2022 PUBLICATIONS CONTINUED

31. Outcomes Following Hypofractionated Stereotactic Radiotherapy to the Cavity After Surgery for Melanoma

Brain Metastases Gallo J, Garimall S, Shanker M, Castelli J, Watkins T, Olson S, Huo M, Foote MC, Pinkham MB. Clin Oncol (R Coll Radiol). 2022 Mar;34(3):179-186. doi: 10.1016/j.clon.2021.09.015.

Epub 2021 Oct 9.

Icon Author: Castelli J, Huo M, Foote MC, Pinkham MB

32. Palbociclib plus letrozole as treatment for postmenopausal women with hormone receptorpositive/human epidermal growth factor receptor 2-negative advanced breast cancer for whom letrozole therapy is deemed appropriate: An expanded access study in Australia and India Loi S, Karapetis CS, McCarthy N, Oakman C, Redfern A, White M, Khasraw M, Doval DC, Gore V, Alam M, Binko J, Lu DR, Kim S, Boyle F. Asia Pac J Clin Oncol. 2022 Dec;18(6):560-569. doi: 10.1111/ajco.13653. Epub 2021 Dec 14.

Icon Author: McCarthy N

33. Patient-derived xenograft models capture genomic heterogeneity in endometrial cancer Bonazzi VF, Kondrashova O, Smith D, Nones K, Sengal AT, Ju R, Packer LM, Koufariotis LT, Kazakoff SH, Davidson AL, Ramarao-Milne P, Lakis V, Newell F, Rogers R, Davies C, Nicklin J, Garrett A, Chetty N, Perrin L, Pearson JV, Patch AM, Waddell N, Pollock PM. Genome Med. 2022 Jan 10;14(1):3. doi: 10.1186/s13073-021-00990-z.

Icon Author: Nicklin J, Garrett A

34. Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1 Saad F, de Bono J, Barthélémy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels JP, Renard V, Maruzzo M, Higano CS, Gurney H, Healy C, Bhattacharyya H, Arondekar B, Niyazov A, Fizazi K. Eur Urol. 2022 Jun 21:S0302-2838(22)02407-1. doi: 10.1016/j.eururo.2022.05.030. Online ahead of print.

Icon Author: Stirling A

35. Patterns of curative treatment for non-small cell lung cancer in New South Wales, Australia Batumalai V, Descallar J, Gabriel G, Delaney GP, Oar A, Barton MB, Vinod SK. Asia Pac J Clin Oncol. 2022 Jul 17. doi: 10.1111/ajco.13811. Online ahead of print.

Icon Author: Oar A

36. Penpulimab, an anti-PD1 IgG1 antibody in the treatment of advanced or metastatic upper gastrointestinal cancers Zheng Y, Mislang ARA, Coward J, Cosman R, Cooper A, Underhill C, Zhu J, Xiong J, Jiang O, Wang H, Xie Y, Zhou Y, Jin X, Li B, Wang ZM, Kwek KY, Xia D, Xia Y, Xu N. Cancer Immunol Immunother. 2022 Oct;71(10):2371-2379. doi: 10.1007/s00262-02203160-1. Epub 2022 Feb 15.

Icon Author: Coward J, Mislang ARA

37. Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14) Kalff A, Khong T, Ramachandran M, Ho PJ, Mollee P, D’Rozario J, Taylor K, Estell J, Norton S, Kemp R, Mitchell AJ, Reynolds J, Kennedy N, Quach H, Spencer A. Haematologica. 2022 Jan 1;107(1):321325. doi: 10.3324/haematol.2021.278655.

Icon Author: Taylor K

38. Practical management of chronic lymphocytic leukemia with acalabrutinib Kuss B, Nagarajan C, Hsieh WS, Cheah CY. Leuk Lymphoma. 2022 Dec;63(12):2785-2794. doi: 10.1080/10428194.2022.2098289. Epub 2022 Jul 19.

Icon Author: Hsieh WS

39. Prospective Surveillance with Compression for Subclinical Lymphedema: Symptoms, Skin, and Quality-of-Life Outcomes Dietrich MS, Gaitatzis K, Koelmeyer L, Boyages J, Abramson VG, McLaughlin SA, Ngui N, Elder E, French J, Hsu J, Hughes TM, Stolldorf DP, Shah C, Ridner SH. Lymphat Res Biol. 2022 Sep 20. doi: 10.1089/lrb.2022.0020. Online ahead of print.

Icon Author: Boyages J

40. Radiotherapy prioritization in 143 national cancer control plans: Correlation with radiotherapy machine availability, geography and income level Wilson BE, Oar A, Rodin D, Bray F, Ferlay J, Polo A, Borras JM, Bourque JM, Malik M, Ynoe de Moraes F, Lievens Y, Stevens LM, Zubizarreta E, Yap ML. Radiother Oncol. 2022 Nov;176:83-91. doi: 10.1016/j.radonc.2022.09.001. Epub 2022 Sep 14.

Icon Author: Oar A

41. Real-world outcomes from use of CDK4/6 inhibitors in the management of advanced/ metastatic breast cancer in Asia Low JL, Lim E, Bharwani L, Wong A, Wong K, Ow S, Lim SE, Lee M, Choo J, Lim J, Chan G, Walsh RJ, Muthu V, Ngoi N, Chong W, Tan SH, Lee SC. Ther Adv Med Oncol. 2022 Dec 18;14:17588359221139678. doi: 10.1177/17588359221139678. eCollection 2022.

Icon Author: Wong K

42. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force Lim KHT, Kong HL, Chang KTE, Tan DSW, Tan IBH, Mohamad F, Soh SY, Pang BN, Soo RA, Choo SP, Hsieh WS, Aung L. Asia Pac J Clin Oncol. 2022 Aug;18(4):394-403. doi: 10.1111/ ajco.13727. Epub 2021 Nov 21.

Icon Author: Kong HL, Hsieh WS, Aung L

43. Results of PD-L1 Analysis of Women Treated with Durvalumab in Advanced Endometrial Carcinoma (PHAEDRA) Smith D, Robledo KP, Yip S, Cummins MM, Kok PS, Lee YC, Friedlander M, Baron-Hay S, Shannon

C, Coward J, Beale P, Goss G, Meniawy T, Lombard J, Spurdle AB, Andrews J, Stockler MR, Mileshkin L, Antill Y; Australia New Zealand Gynaecological Oncology Group (ANZGOG). Cancers (Basel). 2022 Dec 30;15(1):254. doi: 10.3390/cancers15010254.

Icon Author: Coward J

44. Risk factors for breast cancer-related lymphedema in patients undergoing 3 years of prospective surveillance with intervention Koelmeyer LA, Gaitatzis K, Dietrich MS, Shah CS, Boyages J, McLaughlin SA, Taback B, Stolldorf DP, Elder E, Hughes TM, French JR, Ngui N, Hsu JM, Moore A, Ridner SH. Cancer. 2022 Sep 15;128(18):3408-3415. doi: 10.1002/cncr.34377. Epub 2022 Jul 7.

Icon Author: Boyages J

45. Serious Underlying Medical Conditions and COVID-19 Vaccine Hesitancy: A Large Cross-Sectional Analysis from Australia Day D, Grech L, Nguyen M, Bain N, Kwok A, Harris S, Chau H, Chan B, Blennerhassett R, Nott L, Hamad N, Tognela A, Hoffman D, McCartney A, Webber K, Wong J, Underhill C, Sillars B, Winkel A, Savage M, Loe BS, Freeman D, Segelov E, On Behalf Of The Canvaccs Diabvaccs And Msvaccs Investigators. Vaccines (Basel). 2022 May 26;10(6):851. doi: 10.3390/ vaccines10060851.

Icon Author: Nott L, Bain N

46. Spontaneous tumour lysis syndrome complicated by recurrent hypoglycaemia in first presentation of advanced lymphoproliferative disease Head LV, Hancock M, Armitage MC. Emerg Med Australas. 2022 Aug;34(4):658-659. doi: 10.1111/1742-6723.14031.

Epub 2022 Jun 4.

Icon Author: Hancock M

47. Survey of germline variants in cancer-associated genes in young adults with colorectal cancer Mikaeel RR, Young JP, Li Y, Smith E, Horsnell M, Uylaki W, Tapia Rico G, Poplawski NK, Hardingham JE, Tomita Y, Townsend AR, Feng J, Zibat A, Kaulfuß S, Müller C, Yigit G, Wollnik B, Price TJ. Genes Chromosomes Cancer. 2022 Feb;61(2):105-113. doi: 10.1002/gcc.23011. Epub 2021 Nov 18.

Icon Author: Tapia Rico G

48. Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1

Safety Analyses Mehra N, Fizazi K, de Bono JS, Barthélémy P, Dorff T, Stirling A, Machiels JP, Bimbatti D, Kilari D, Dumez H, Buttigliero C, van Oort IM, Castro E, Chen HC, Di Santo N, DeAnnuntis L, Healy CG, Scagliotti GV. Oncologist. 2022 Oct 1;27(10):e783-e795. doi: 10.1093/oncolo/oyac172.

Icon Author: Stirling A

49. The optimal management of brain metastases from gestational trophoblastic neoplasia Tsai J, Vellayappan B, Venur V, McGranahan T, Gray H, Urban RR, Tseng YD, Palmer J, Foote M, Mayr NA, Combs SE, Sahgal A, Chang EL, Lo SS. Expert Rev Anticancer Ther. 2022 Mar;22(3):307-315. doi: 10.1080/14737140.2022.2038566. Epub 2022 Feb 13.

Icon Author: Foote M

50. The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting Choi JDW, Hughes TMD, Marx G, Boyages J, Rutovitz J, Hasovits C, Parasyn A, Edirimanne S, Ngui NK. Breast J. 2022 Jan 31;2022:1199245. doi: 10.1155/2022/1199245. eCollection 2022.

Icon Author: Boyages J

51. Variability of gross tumour volume delineation: MRI and CT based tumour and lymph node delineation for lung radiotherapy Kumar S, Holloway L, Boxer M, Yap ML, Chlap P, Moses D, Vinod S. Radiother Oncol. 2022 Feb;167:292-299. doi: 10.1016/j.radonc.2021.11.036.

Epub 2021 Dec 8.

Icon Author: Boxer M

52. Varian ethos online adaptive radiotherapy for prostate cancer: Early results of contouring accuracy, treatment plan quality, and treatment time Byrne M, ArchibaldHeeren B, Hu Y, Teh A, Beserminji R, Cai E, Liu G, Yates A, Rijken J, Collett N, Aland T. J Appl Clin Med Phys. 2022 Jan;23(1):e13479. doi: 10.1002/acm2.13479. Epub 2021 Nov 29.

Icon Author: Byrne M, Archibald-Heeren B, Hu Y, Teh A, Beserminji R, Cai E, Liu G, Yates A, Rijken J, Collett N, Aland T

53. Weight Gain and Lymphedema After Breast Cancer Treatment: Avoiding the Catch-22? Boyages J, Cave AE, Naidoo D, Ee CCL. Lymphat Res Biol. 2022 Aug;20(4):409-416. doi: 10.1089/lrb.2020.0048. Epub 2021 Nov 8.

Icon Author: Boyages J

54. What Asian-Pacific Countries Could Build Upon the United States’ Oncology Care Model? Chen J, Wee S, Sally Ho SL. JCO Oncol Pract. 2022 Jan;18(1):1-3. doi: 10.1200/OP.21.00367. Epub 2021 Aug 2.

Icon Author: Wee S